AUTHORS
Makoto Iwasaki, MD, PhD, Eric Minwei Liu, PhD2, Corben Yuwai Wong, BS3, Caroline MacVicar4, Anna Rider5, Aliyah Sohani, MD6, Valentina Nardi, MD7, Govind Bhagat, MD8, Teresa Palomero, PhD9, Robert Willim, MD10, Meredith Nichols, MD11, Esther Rheinbay, PhD12, Josie Ford, BSc13, Kusha Chopra, BS14, Khyati Kariya, PhD15, Eva Brill16, Vishnu Udayakumar Sunita Kumary17, Bryan J. Venters, PhD18, Martis W. Cowles, PhD19, Michael-Christopher Keogh, PhD20, Eric Jacobsen, MD21, Enrica Marchi, MD, PhD22, Stefan K Barta, MD23, Carrie van der Weyden, MD24, Tatyana Feldman, MD25, Christina Poh, MD26, Basem William, MD, MRCP(UK), FACP27, Estelle Verburgh, MD, PhD28, Zainab Mohamed29, Nathan Roberts, MD30, Danielle Blunt, BMBS31, Takashi Sakamoto, MD, PhD32, Yumeng Zhang, MD33, Bradley Haverkos, MD34, Mitsumasa Watanabe, MD35, Nora Bennani, MD36, Yun Kyoung Tiger, MD, PhD37, Jonathan Brammer, MD38, Pamela Allen, MD39, Deepa Jagadeesh, MD, MPH40, Maya deepti Srinivasan, MD, MSc41, John Mark L Sloan Jr, MD42, Lauren Shea, MD43, Harsh Rohit Shah, DO44, Sonali Smith, MD, FASCO45, Nazila Shafagati, MD46, Bhagirathbhai Dholaria, MD, FACP47, Jeffrey Barnes, MD, PhD48, Salvia Jain, MD49
AFFILIATIONS
1 Massachusetts General Hospital, Boston, Massachusetts, United States
2 Massachusetts Institute of Technology, Cambridge, Massachusetts, United States
3 Massachusetts General Hospital, Boston, Massachusetts, United States
4 Massachusetts General Hospital, Boston, Massachusetts, United States
5 Massachusetts General Hospital, Boston, Massachusetts, United States
6 Massachusetts General Hospital, Boston, Massachusetts, United States
7 Massachusetts General Hospital, Boston, Massachusetts, United States
8 Saint Louis University, Saint Louis, Missouri, United States
9 Columbia University Irving Medical Center, New York, New York, United States
10 Bidmc Hmfp, Boston, Massachusetts, United States
11 Cleveland Clinic, Cleveland, Ohio, United States
12 Massachusetts General Hospital, Boston, Massachusetts, United States
13 Massachusetts General Hospital, Boston, Massachusetts, United States
14 Massachusetts General Hospital, Boston, Massachusetts, United States
15 Massachusetts General Hospital, Boston, Massachusetts, United States
16 Epicypher Inc., Durham, North Carolina, United States
17 Epicypher Inc., Durham, North Carolina, United States
18 Epicypher Inc., Durham, North Carolina, United States
19 Epicypher Inc., Durham, North Carolina, United States
20 Epicypher Inc., Durham, North Carolina, United States
21 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
22 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
23 University of Pennsylvania, Philadelphia, Pennsylvania, United States
24 Peter Maccallum Cancer Centre, Melbourne CBD, Victoria, Australia
25 Hackensack Meridian Health Network, Hackensack, New Jersey, United States
26 City of Hope National Medical Center, Duarte, California, United States
27 Ohio State University, Columbus, Ohio, United States
28 University Of Cape Town, Cape Town, South Africa
29 University Of Cape Town, Cape Town, South Africa
30 University of Virginia, Charlottesville, Virginia, United States
31 Royal Adelaide Hospital, Adelaide Central Business District, South Australia, Australia
32 Kyoto University Hospital, Kyoto, Japan
33 Moffitt Cancer Center, Tampa, Florida, United States
34 University of Colorado-Denver, Denver, Colorado, United States
35 Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Japan
36 Mayo Clinic, Rochester, Minnesota, United States
37 Mayo Clinic, Rochester, Minnesota, United States
38 Ohio State University Wexner Medical Center, Columbus, Ohio, United States
39 Emory University, Atlanta, Georgia, United States
40 Cleveland Clinic, Cleveland, Ohio, United States
41 Boston Medical Center, Boston, Massachusetts, United States
42 Boston Medical Center, Boston, Massachusetts, United States
43 University of Alabama at Birmingham Medical Center, Birmingham, Alabama, United States
44 Huntsman Cancer Institute, Salt Lake City, Utah, United States
45 University of Chicago, Chicago, Illinois, United States
46 University of Chicago, Chicago, Illinois, United States
47 Vanderbilt University Medical Center, Nashville, Tennessee, United States
48 Massachusetts General Hospital, Boston, Massachusetts, United States
49 Massachusetts General Hospital, Boston, Massachusetts, United States
ABSTRACT
Protein-coding gene alterations in mature T- and NK-cell lymphomas (MTNKL) are well characterized, but the non-coding regulatory landscape governing oncogenic transcription remains poorly defined. Super-enhancers (SEs), large clustered cis-regulatory elements, impose tumor-specific transcriptional dependencies. Prior studies identified subtype-specific SE programs, but no systematic cross-subtype map exists in MTNKL. We investigated whether SE-regulated transcription-factor (TF) circuits create shared and therapeutically actionable dependencies across MTNKL subtypes.
We profiled 36 MTNKL cell lines, 7 patient-derived xenografts, 3 primary PBMC samples, and 13 normal T/NK references. SEs and active regulatory elements were mapped by H3K27ac CUT&RUN/Tag, ATAC-seq and RNA-seq. SEs were called with MACS3 and stitched with ROSE. Core transcriptional regulatory circuitry (CRC) was inferred with COLTRON, and gene regulatory networks (GRN) were reconstructed with ANANSE. TF motif activities in SE-associated open chromatin were inferred with chromVAR. Additionally active transcription was assayed directly in 31 patient-derived FFPE specimens from the PETAL consortium (nodal T-follicular helper cell lymphoma (nTFHL): n=10; PTCL not otherwise specified (NOS): n=8; ALK− anaplastic large cell lymphoma (ALCL): n=3; ALK+ ALCL: n=3; extranodal NK/T-cell lymphoma (ENKTL): n=7) and 5 normal cell references (CD4+ T n=3, PBMC n=2) by FFPE-Cleavage Under Targeted Accessible Chromatin (CUTAC) targeting RNA polymerase II Ser5-phosphorylation (RNAPII-S5P) (Henikoff S et al., Science 2025). Promoters were defined as peaks <2 kb from a transcription start site (TSS) assigned to the nearest gene and distal enhancers as peaks ≥2 kb from a TSS overlapping the consensus SE/ATAC-seq atlas of MTNKL cell lines. Dependencies were integrated from genome-wide DepMap CRISPR data (1,208 lines), and Golcadomide combinations were assessed by combination index (CI), Bliss, and highest single agent (HSA) within the most synergistic 3×3 dose window.
We defined 7,754 union SE elements, resolving constitutive SEs shared with normal T cells, tumor-specific core/ pan-MTNKL SEs, and subtype-specific SEs. AP-1 family TF motifs were significantly enriched across nTFHL, PTCL-NOS, ALCL, and ENKTL, indicating shared activity across MTNKL subtypes. BATF3 was a recurrent tumor-specific, SE-driven CRC component, whereas IKZF1 was an autoregulated, SE-associated CRC component shared by tumor and normal models. In enhancer-based GRNs inferred with ANANSE, BATF3 network influence was restricted to ALCL and ATLL, indicating broad SE/CRC membership but subtype-restricted differential network activity. In patient FFPE MTNKL specimens, RNAPII-S5P FFPE-CUTAC peaks at distal enhancers showed AP-1 and IRF4 motif enrichment vs normal CD4+ T cells in all five subtypes and enhanced promoter transcription in four subtypes other than nTFHL (BATF3/IRF4 HOCOMOCO log2 motif enrichment: nTFHL 0.36,0.43; PTCL-NOS 0.61,0.33; ALK- ALCL 0.68,0.68; ALK+ ALCL 1.00,0.37; ENKTL 0.76,0.46; all adjusted p ≤ 1.2e-2; DESeq2: nTFHL 0.61, 1.27 (adjusted p=0.14, 0.26); PTCL-NOS 1.55, 1.92; ALK− ALCL 2.00, 2.31; ALK+ ALCL 1.81, 1.51; ENKTL 2.02, 1.92; adjusted p ≤ 5.6×10⁻³), which validates activation of the pan-MTNKL BATF3-IRF4 transcriptional axis in primary patient samples. In DepMap, BATF3 was selectively essential in MTNKL lines (n=11) versus other lineages, with co-essentiality with IKZF1 and IRF4. Golcadomide, a CELMoD primarily targeting IKZF1/3, degraded IKZF1 within 4 h yielding single-agent activity in MTNKL cell lines. In Karpas-299, enhancers losing H3K27ac 4 h after golcadomide (5 nM) were enriched for E2F2, E2F4, E2F8, and NFKB2 motifs. Golcadomide synergized with the PI3K inhibitor duvelisib in Ki-JK, Karpas-299, My-La, and SMZ1 (CI < 1 with positive Bliss- and HSA-MSA in all four). We will present the CRISPR screening data for Golcadomide versus DMSO treated MTNKL cells to define the MTNKL-specific vulnerabilities after IKZF1 degradation including results from in vivo combination studies of golcadomide and duvelisib.
Integrated epigenomic profiling, active-transcription mapping in FFPE patient samples, and functional dependency mapping identify an SE-driven IKZF1-BATF3-IRF4 circuit as a shared vulnerability across MTNKL subtypes. This program is therapeutically accessible through CELMoD-mediated IKZF1 degradation and may be further enhanced by PI3K inhibition.
DISCLOSURES
Makoto Iwasaki, MD, PhD: No relevant conflicts of interest to declare.